Clinical trials: Breast Tumour
HER-2 Positive Breast Cancer, Metastatic Neoplasm
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with…
- Trial name
- SOPHIA (NCT02492711)
- Testing
- Margetuximab, Trastuzumab, Physician's choice of chemotherapy.
- Where
- 167 sites in United States, Austria and 16 more
- Volunteers
- 624 people
- Sponsor
- MacroGenics
Triple Negative Breast Neoplasms
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. It will find out what side effects happen when participants get these two drugs.
- Trial name
- NCT03310957
- Testing
- ladiratuzumab vedotin, Pembrolizumab
- Where
- 50 sites in United States, Germany and 2 more
- Volunteers
- 185 people
- Sponsor
- Seagen Inc.
Breast Cancer
Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density
It has been shown that women who have dense breasts have an increased risk of breast cancer compared with women whose breasts are less dense.
- Trial name
- NCT00418236
- Where
- 37 sites in United States, Argentina and 12 more
- Volunteers
- 400 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Breast Cancer Female
Effect of Quilting Sutures on Post-operative Drainage After Mastectomy and/or Axillary Lymph Node Dissection
Breast cancer is the most frequent type of cancer among Swiss women (5'700 cases diagnosed every year). Mastectomy is indicated when breast conservative surgery is not possible or by patient wish.
- Trial name
- Quilting (NCT03902977)
- Testing
- quilting, conventional suture
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- Lindenhofgruppe AG
Breast Neoplasms
An Observational Study Evaluating the Productivity and Health-Related Quality of Life of People With HER2 Positive Breast Cancer
The purpose of this study is to compare productivity (in terms of work or daily activity) and generic and disease-specific health-related quality of life of participants with HER2 positive early breast cancer currently receiving…
- Trial name
- NCT03099200
- Testing
- No Intervention
- Where
- 14 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
TNBC
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HB0025 administered with chemotherapy in participants with locally advanced or metastatic triple-negative…
- Trial name
- NCT07376629
- Testing
- HB0025 20 mg/kg plus nab-paclitaxel, HB0025 10 mg/kg plus nab-paclitaxel
- Where
- 23 sites in China
- Volunteers
- 60 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Breast Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
This observational study will assess the median time of treatment duration and the safety of Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer.
- Trial name
- NCT01215123
- Testing
- Bevacizumab
- Where
- 12 sites in Argentina
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced or Metastatic Breast Cancer
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
The purpose of this study is to evaluate the effectiveness and safety of capivasertib + fulvestrant treatment administration in patients with locally advanced (inoperable) or metastatic HR+ / HER2- breast cancer with…
- Trial name
- CAPItana (NCT06764186)
- Testing
- Fulvestrant, Capivasertib
- Where
- 17 sites in Spain
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Breast Neoplasms, Peritoneal Neoplasms
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
Monoclonal antibodies can transport and deliver radioactive elements capable of releasing sufficient amounts of energy to destroy tumor cells.
- Conditions
- Breast Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT01384253
- Testing
- ²¹²Pb-TCMC-Trastuzumab, trastuzumab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Orano Med LLC
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Breast Cancer
Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)
Primary Objective: To assess the incidence rate of dose-limiting toxicity and to confirm the recommended dose as well as the maximum tolerated dose of SAR439859 administered as monotherapy to Japanese postmenopausal women with…
- Trial name
- AMEERA-2 (NCT03816839)
- Testing
- Amcenestrant (SAR439859)
- Where
- 3 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Sanofi
Neoplasms, Breast
Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer
This study will examine specific biomarkers in primary invasive breast cancer and explore their correlation with patient outcome following standard neoadjuvant treatment.
- Trial name
- NCT01476111
- Where
- 29 sites in United States, Belgium and 4 more
- Volunteers
- 117 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib
The aim of this study was to assess the effectiveness, safety, and tolerability of ribociclib in Indian women with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced breast…
- Trial name
- RESONATE (NCT07363434)
- Where
- United States
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Breast Cancer
Investigation of a Digital Healthy Habits Program for Individuals With Breast Cancer
This mixed methods study will involve obtaining user feedback on the first 4 weeks of the Healthy Habits for Cancer (HCC) Program.
- Conditions
- Cancer, Breast Cancer, Obesity, Overweight and Obesity
- Trial name
- NCT04967209
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Noom Inc.
Advanced Glioblastoma, Advanced Colorectal Cancer
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
ONC201 is a new potential drug that kills cancer cells but not normal cells in laboratory studies. This clinical trial will be the first evaluation of ONC201 in humans and will enroll patients with advanced cancer.
- Conditions
- Advanced Glioblastoma, Advanced Colorectal Cancer, Advanced Triple-negative Breast Cancer, Advanced Non-small Cell Lung Cancer
- Trial name
- NCT02038699
- Testing
- ONC201
- Where
- United States
- Sponsor
- Jazz Pharmaceuticals
Breast Cancer
Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications
Comparative Evaluation of Gen1B (OA-16-1S) duplex OA/US probe versus Gen1 (OA-16-1) duplex OA/US probe in Healthy Subjects
- Trial name
- NCT03845907
- Testing
- Gen 1B, Gen 1
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Seno Medical Instruments Inc.
Advanced Solid Tumors
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2).
- Trial name
- NCT05941507
- Testing
- LCB84, Anti-PD-1 monoclonal antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- LigaChem Biosciences, Inc.
Triple Negative Breast Cancer
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
- Trial name
- NCT06908928
- Testing
- bulumtatug fuvedotin
- Where
- 7 sites in United States
- Volunteers
- 52 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Breast Neoplasms
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients
The primary objective of this study is to assess the pathological Complete Response (pCR) rate by treatment arm (according to Chevallier criteria).
- Trial name
- SATIN (NCT00485979)
- Testing
- larotaxel (XRP9881), docetaxel, trastuzumab
- Where
- 8 sites in Belgium, Brazil and 6 more
- Volunteers
- 330 people
- Sponsor
- Sanofi
Metastatic Breast Cancer
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
This is an open-label, multicenter, single-arm safety study evaluating the safety and tolerability of the lasofoxifene and abemaciclib combination for the treatment of pre- and postmenopausal women with locally advanced or…
- Trial name
- ELAINEII (NCT04432454)
- Testing
- Lasofoxifene and abemaciclib (VERZENIO (R)).
- Where
- 16 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sermonix Pharmaceuticals Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.